Recombinant human soluble thrombomodulin administration improves sepsis-induced disseminated intravascular coagulation and mortality: A retrospective cohort study

Thrombosis Journal

Volumn 11, Issue 1, 2013, Pages

  Kato, Takahiro ^a   Sakai, Takamasa ^b   Kato, Miki ^a   Hagihara, Mao ^a   Hasegawa, Takaaki ^a   Matsuura, Katsuhiko ^a   Nakagawa, Takashi ^a  

^a AICHI MEDICAL UNIVERSITY   (Japan)

^b MEIJO UNIVERSITY   (Japan)

Author keywords

Anticoagulant; Critically ill patient; DIC score; Disseminated intravascular coagulation; Intensive care unit; JAAM; Multiple organ failure; Sepsis; Thrombomodulin

Indexed keywords

D DIMER; RECOMBINANT THROMBOMODULIN;

ADULT; AGED; ARTICLE; BLOOD CLOTTING TEST; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DISSEMINATED INTRAVASCULAR CLOTTING; DISSEMINATED INTRAVASCULAR COAGULATION MARKER; FEMALE; HUMAN; MALE; MORTALITY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; SEPSIS;

EID: 84873939761     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/1477-9560-11-3     Document Type: Article

References (20)

1. Wada H, Wakita Y, Nakase T, Shimura M, Hiyoyama K, Nagaya S, Mori Y, Shiku H. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun, Mie DIC Study Group. Thromb Haemost 1995, 74:848-852.
2. Dhainaut JF, Yan SB, Jpyce DE, Pettila V, Basson B, Brandt T, Sundin DP, Levis M. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004, 2:1924-1933. 10.1111/j.1538-7836.2004.00955.x, 15550023.
3. Taylor FB, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001, 86:1327-1330.
4. Kobayashi N, Maekawa T, Takada M, Tanaka H, Gonmori H. Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan. Bibl Haematol 1983, 49:265-275.
5. Gando S, Saitoh D, Ogura H, Mayumi T, Koseki K, Ikeda T, Ishikura H, Iba T, Ueyama M, Eguchi Y, Ohtomo Y, Okamoto K, Kushimoto S, Endo S, Shimazaki S. Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: results of a multicenter, prospective survey. Crit Care Med 2006, 34:625-631.
6. Gando S, Wada H, Asakura H, Iba T, Eguchi Y, Okamoto K, Ohtomo Y, Kawasugi K, Koga S, Koseki K, Tsuji H, Mayumi T, Murata A, Nakagawa M, Endo S. Evaluation of new Japanese diagnostic criteria for disseminated intravascular coagulation in critically ill patients. Clin Appl Thromb Haemost 2005, 11:71-76.
7. Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, Hirayama A, Matsuda T, Asakura H, Nakashima M, Aoki N. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007, 5:31-41. 10.1111/j.1538-7836.2006.02267.x, 17059423.
8. Yamakawa K, Fujimi S, Mohri T, Matsuda H, Nakamori Y, Hirose T, Tasaki O, Ogura H, Kuwagata Y, Hamasaki T, Shimazu T. Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study. Crit Care 2011, 15:R123. Epub, 10.1186/cc10228, 3218981, 21569368.
9. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36:296-327. 10.1097/01.CCM.0000298158.12101.41, 18158437.
10. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007, 11:R31. Epub, 10.1186/cc5713, 2206446, 17331245.
11. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol 2009, 145:24-33. 10.1111/j.1365-2141.2009.07600.x, 19222477.
12. Mohri M, Gonda Y, Oka M, Aoki Y, Gomi K, Kiyota T, Sugihara T, Yamamoto S, Ishida T, Maruyama I. The antithrombotic effects of recombinant human soluble thrombomodulin (rhsTM) on tissue factor-induced disseminated intravascular coagulation in crab-eating monkeys (Macaca fascicularis). Blood Coagul Fibrinolysis 1997, 8:274-283. 10.1097/00001721-199707000-00003, 9282791.
13. Iba T, Nakarai E, Takayama T, Nakajima K, Saraoka T, Ohno Y. Combination effect of antithrombin and recombinant human soluble thrombomodulin in a lipopolysaccharide induced rat sepsis model. Crit Care 2009, 13:R203. 10.1186/cc8210, 2811901, 20003418.
14. Van de Wouwer M, Collen D, Conway EM. Thrombomodulin-protein C-EPCR system integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol 2004, 24:1374-1383. 10.1161/01.ATV.0000134298.25489.92, 15178554.
15. Nakazono O, Suzuki M, Sata M, Sugimoto E, Suzuki H. Anticoagulant activities of recombinant human soluble thrombomodulin (ART-123). Jpn Pharmacol Ther 2006, 34:347-353.
16. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709. 10.1056/NEJM200103083441001, 11236773.
17. Benstetter M, Haubenreisser S. Xigris (drotrecogin alfa (activated)) to be withdrawn due to lack of efficacy http://www.webcitation.org/62icYBgm1.
18. Gentry CA, Gross KB, Sud B, Drevets DA. Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautions. Crit Care Med 2009, 37:19-25. 10.1097/CCM.0b013e318192843b, 19050637.
19. Sadaka F, O'Brien J, Migneron M, Stortz J, Vanston A, Taylor RW. Activated protein C in septic shock: a propensity-matched analysis. Crit Care 2011, 15:R89. Epub, 10.1186/cc10089, 3219349, 21385410.
20. Wang Y, Thiyagarajan M, Chow N, Singh I, Guo H, Davis TP, Zlokovic BV. Differential neuroprotection and risk for bleeding from activated protein C with varying degrees of anticoagulant activity. Stroke 2009, 40:1864-1869. 10.1161/STROKEAHA.108.536680, 2691176, 19057019.